Patients with type 2 diabetes mellitus (T2DM) can have multiple comorbidities and premature mortality due to atherosclerotic cardiovascular disease, hospitalization with heart failure and/or chronic kidney disease. Traditional drugs that lower glucose, such as metformin, or that treat high blood pressure and blood levels of lipids, such as renin–angiotensin-system inhibitors and statins, have organ-protective effects in patients with T2DM. Amongst patients with T2DM treated with these traditional drugs, randomized clinical trials have confirmed the additional cardiorenal benefits of sodium–glucose co-transporter 2 inhibitors (SGLT2i), glucagon-like peptide 1 receptor agonists (GLP1RA) and nonsteroidal mineralocorticoid receptor antagonists. The cardiorenal benefits of SGLT2i extended to patients with heart failure and/or chronic kidney disease without T2DM, whereas incretin-based therapy (such as GLP1RA) reduced cardiovascular events in patients with obesity and T2DM. However, considerable care gaps exist owing to insufficient detection, therapeutic inertia and poor adherence to these life-saving medications. In this Review, we discuss the complex interconnections of cardiorenal–metabolic diseases and strategies to implement evidence-based practice. Furthermore, we consider the need to conduct clinical trials combined with registers in specific patient segments to evaluate existing and emerging therapies to address unmet needs in T2DM.
In patients with type 2 diabetes mellitus (T2DM), improved risk factor control and the use of renin–angiotensin system inhibitors and statins have reduced the incidence of cardiovascular-renal events and related deaths.
Despite these improvements, cardiovascular and/or renal events and related death in patients with T2DM remain higher than in patients without T2DM.
Among patients with newly diagnosed or short duration of T2DM, early intensive glycaemic control to achieve near-normal blood levels of glucose might offer potential legacy effects on cardiovascular outcomes.
Sodium–glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists are preferred to prevent cardiovascular and/or renal complications and related death among patients with T2DM at high cardiorenal risk.
Multi-stakeholder engagement is needed to combine research and practice to close treatment gaps in guideline-directed medical therapy among patients at high cardiorenal risk through care re-organization with ongoing benchmarking.
Future research should address data gaps in risk stratification for cardiorenal complications, while clinical trials are required in women and patients with T2DM who are young or at low cardiorenal risk to address unmet needs.
This is a preview of subscription content, access via your institution
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
International Diabetes Federation. IDF Diabetes Atlas 10th edn (IDF, 2021).
Franks, P. W. & Poveda, A. Lifestyle and precision diabetes medicine: will genomics help optimise the prediction, prevention and treatment of type 2 diabetes through lifestyle therapy? Diabetologia 60, 784–792 (2017).
Chan, J. C. N. et al. The Lancet Commission on Diabetes: using data to transform diabetes care and patient lives. Lancet 396, 2019–2082 (2021).
GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396, 1223–1249 (2020).
Magliano, D. J. et al. Trends in incidence of total or type 2 diabetes: systematic review. BMJ 366, l5003 (2019).
American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care 41, 917–928 (2018).
Magliano, D. J., Martin, V. J., Owen, A. J., Zomer, E. & Liew, D. The productivity burden of diabetes at a population level. Diabetes Care 41, 979–984 (2018).
Gregg, E. W., Hora, I. & Benoit, S. R. Resurgence in diabetes-related complications. JAMA 321, 1867–1868 (2019).
Rossing, P. et al. Executive summary of the KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease: an update based on rapidly emerging new evidence. Kidney Int. 102, 990–999 (2022).
Draznin, B. et al. 4. Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes-2022. Diabetes Care 45, S46–S59 (2022).
Flegal, K. M., Kit, B. K., Orpana, H. & Graubard, B. I. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 309, 71–82 (2013).
Kim, Y. H. et al. Underweight increases the risk of end-stage renal diseases for type 2 diabetes in Korean population: data from the national health insurance service health checkups 2009–2017. Diabetes Care 43, 1118–1125 (2020).
Yokomichi, H. et al. All-cause and cardiovascular disease mortality in underweight patients with diabetic nephropathy: BioBank Japan cohort. J. Diabetes Investig. 12, 1425–1429 (2021).
Di Angelantonio, E. et al. Association of cardiometabolic multimorbidity with mortality. JAMA 314, 52–60 (2015).
Magliano, D. J. et al. Trends in all-cause mortality among people with diagnosed diabetes in high-income settings: a multicountry analysis of aggregate data. Lancet Diabetes Endocrinol. 10, 112–119 (2022).
Harding, J. L., Pavkov, M. E., Gregg, E. W. & Burrows, N. R. Trends of nontraumatic lower-extremity amputation in end-stage renal disease and diabetes: United States, 2000–2015. Diabetes Care 42, 1430–1435 (2019).
Ling, W. et al. Global trend of diabetes mortality attributed to vascular complications, 2000–2016. Cardiovasc. Diabetol. 19, 182 (2020).
Wu, H. et al. Trends in diabetes-related complications in Hong Kong, 2001–2016: a retrospective cohort study. Cardiovasc. Diabetol. 19, 60 (2020).
Ali, M. K., Pearson-Stuttard, J., Selvin, E. & Gregg, E. W. Interpreting global trends in type 2 diabetes complications and mortality. Diabetologia 65, 3–13 (2022).
Rawshani, A. et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 379, 633–644 (2018).
Wu, H. et al. Secular trends in all-cause and cause-specific mortality rates in people with diabetes in Hong Kong, 2001-2016: a retrospective cohort study. Diabetologia 63, 757–766 (2020).
Norhammar, A. et al. Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: a multinational, observational study across 12 countries. Diabetes Obes. Metab. 24, 1277–1287 (2022).
Ahlqvist, E. et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 6, 361–369 (2018).
Xiong, X. F. et al. Identification of two novel subgroups in patients with diabetes mellitus and their association with clinical outcomes: a two-step cluster analysis. J. Diabetes Investig. 12, 1346–1358 (2021).
Grundy, S. M. et al. Diabetes and cardiovascular disease. Circulation 100, 1134–1146 (1999).
Kannel, W. B. & McGee, D. L. Diabetes and cardiovascular disease. the Framingham study. JAMA 241, 2035–2038 (1979).
American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2022. Diabetes Care 45, S144–s174 (2022).
Poznyak, A. et al. The diabetes mellitus–atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation. Int. J. Mol. Sci. 21, 1835 (2020).
Creager, M. A., LüScher, T. F., Cosentino, F. & Beckman, J. A. Diabetes and vascular disease. Circulation 108, 1527–1532 (2003).
Giugliano, D., Maiorino, M. I., Bellastella, G. & Esposito, K. The residual cardiorenal risk in type 2 diabetes. Cardiovasc. Diabetol. 20, 36 (2021).
Giugliano, D., Maiorino, M. I., Bellastella, G. & Esposito, K. Glycemic control in type 2 diabetes: from medication nonadherence to residual vascular risk. Endocrine 61, 23–27 (2018).
Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015).
Wiviott, S. D. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 380, 347–357 (2019).
Neal, B. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644–657 (2017).
Cherney, D. Z., Kanbay, M. & Lovshin, J. A. Renal physiology of glucose handling and therapeutic implications. Nephrol. Dial. Transplant. 35 (Suppl. 1), i3–i12 (2020).
Kashiwagi, A. & Maegawa, H. Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus. J. Diabetes Investig. 8, 416–427 (2017).
Thomas, M. C. & Cherney, D. Z. I. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia 61, 2098–2107 (2018).
Inzucchi, S. E. et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care 41, 356–363 (2018).
Hilton, P. J. Na+ transport in hypertension. Diabetes Care 14, 233–239 (1991).
Ferrannini, E. et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J. Clin. Invest. 124, 499–508 (2014).
Tomita, I. et al. SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition. Cell Metab. 32, 404–419.e6 (2020).
Rosenstock, J. & Ferrannini, E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 38, 1638–1642 (2015).
Drucker, D. J. The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 24, 15–30 (2016).
Burgmaier, M. et al. Glucagon-like peptide-1 (GLP-1) and its split products GLP-1(9-37) and GLP-1(28-37) stabilize atherosclerotic lesions in apoe-/- mice. Atherosclerosis 231, 427–435 (2013).
Nyström, T. et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am. J. Physiol. Endocrinol. Metab. 287, E1209–1215 (2004).
Sattar, N. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 9, 653–662 (2021).
Joseph, J. J. et al. Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association. Circulation 145, e722–e759 (2022).
Emdin, C. A. et al. Blood pressure lowering in type 2 diabetes. A systematic review and meta-analysis. JAMA 313, 603–615 (2015).
Cushman, W. C. et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1575–1585 (2010).
Wright, J. T. Jr et al. A randomized trial of intensive versus standard blood-pressure control. N. Engl. J. Med. 373, 2103–2116 (2015).
Buckley, L. F. et al. Effect of intensive blood pressure control in patients with type 2 diabetes mellitus over 9 years of follow-up: a subgroup analysis of high-risk ACCORDION trial participants. Diabetes Obes. Metab. 20, 1499–1502 (2018).
Kearney, P. M. et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371, 117–125 (2008).
Baigent, C. et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376, 1670–1681 (2010).
Giugliano, R. P. et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus. Circulation 137, 1571–1582 (2018).
Keech, A. et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366, 1849–1861 (2005); erratum 368, 1415 (2006).
Chew, E. Y. et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N. Engl. J. Med. 363, 233–244 (2010).
Sabatine, M. S. et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med. 376, 1713–1722 (2017).
Sabatine, M. S. et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 5, 941–950 (2017).
Ray, K. K. et al. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 7, 618–628 (2019).
Duckworth, W. et al. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 360, 129–139 (2009).
Reaven, P. D. et al. Intensive glucose control in patients with type 2 diabetes — 15-year follow-up. N. Engl. J. Med. 380, 2215–2224 (2019).
Turnbull, F. M. et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52, 2288–2298 (2009).
Barer, Y., Cohen, O. & Cukierman-Yaffe, T. Effect of glycaemic control on cardiovascular disease in individuals with type 2 diabetes with pre-existing cardiovascular disease: a systematic review and meta-analysis. Diabetes Obes. Metab. 21, 732–735 (2019).
Wong, M. G., Heerspink, H. J. L. & Perkovic, V. ACCORDION: ensuring that we hear the music clearly. Clin. J. Am. Soc. Nephrol. 13, 1621–1623 (2018).
Agrawal, L. et al. Long-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetologia 61, 295–299 (2018).
Wong, M. G. et al. Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON. Diabetes Care 39, 694–700 (2016).
Wyatt, C. M. & Cattran, D. C. Intensive glycemic control and the risk of end-stage renal disease: an ADVANCE in the management of diabetes? Kidney Int. 90, 8–10 (2016).
Folz, R. & Laiteerapong, N. The legacy effect in diabetes: are there long-term benefits? Diabetologia 64, 2131–2137 (2021).
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R. & Neil, H. A. 10-Year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 359, 1577–1589 (2008).
Matthews, D. R. et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet 394, 1519–1529 (2019).
Echouffo-Tcheugui, J. B. et al. Visit-to-visit glycemic variability and risks of cardiovascular events and all-cause mortality: the ALLHAT study. Diabetes Care 42, 486–493 (2019).
Ceriello, A. et al. HbA1c variability predicts cardiovascular complications in type 2 diabetes regardless of being at glycemic target. Cardiovasc. Diabetol. 21, 13 (2022).
Griffin, S. J., Leaver, J. K. & Irving, G. J. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia 60, 1620–1629 (2017).
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352, 854–865 (1998).
Chow, E., Yang, A., Chung, C. H. L. & Chan, J. C. N. A clinical perspective of the multifaceted mechanism of metformin in diabetes, infections, cognitive dysfunction, and cancer. Pharmaceuticals 15, 442 (2022).
Yang, A. et al. Attenuated risk association of end-stage kidney disease with metformin in type 2 diabetes with eGFR categories 1-4. Pharmaceuticals 15, 1140 (2022).
Hong, J. et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care 36, 1304–1311 (2013).
Bergmark, B. A. et al. Metformin use and clinical outcomes among patients with diabetes mellitus with or without heart failure or kidney dysfunction: observations from the SAVOR-TIMI 53 trial. Circulation 140, 1004–1014 (2019).
White, W. B. et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med. 369, 1327–1335 (2013).
Scirica, B. M. et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 369, 1317–1326 (2013).
Rosenstock, J. et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes. JAMA 322, 1155 (2019).
Green, J. B. et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 373, 232–242 (2015).
Rosenstock, J. et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk. JAMA 321, 69 (2019).
Pfeffer, M. A. et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N. Engl. J. Med. 373, 2247–2257 (2015).
Holman, R. R. et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 377, 1228–1239 (2017).
Marso, S. P. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311–322 (2016).
Husain, M. et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 381, 841–851 (2019).
Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834–1844 (2016).
Gerstein, H. C. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394, 121–130 (2019).
Giugliano, D. et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc. Diabetol. 20, 189 (2021).
Tuttle, K. R. et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 6, 605–617 (2018).
Cannon, C. P. et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N. Engl. J. Med. 383, 1425–1435 (2020).
Kosiborod, M. et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study. J. Am. Coll. Cardiol. 71, 2628–2639 (2018).
McMurray, J. J. V. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381, 1995–2008 (2019).
Solomon, S. D. et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N. Engl. J. Med. 387, 1089–1098 (2022).
Packer, M. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 383, 1413–1424 (2020).
Anker, S. D. et al. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med. 385, 1451–1461 (2021).
Voors, A. A. et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat. Med. 28, 568–574 (2022).
Bhatt, D. L. et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N. Engl. J. Med. 384, 117–128 (2021).
Wanner, C. et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375, 323–334 (2016).
Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295–2306 (2019).
Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436–1446 (2020).
EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2204233 (2022).
Center for Drug Evaluation and Research. Guidance for industry: diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes (CBER, 2008).
Cefalu, W. T. et al. Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a Diabetes Care Editors’ Expert Forum. Diabetes Care 41, 14–31 (2018).
Hill, A. B. The environment and diseases: association or causation? Proc. R. Soc. Med. 58, 295–300 (1965).
Ke, C., Shah, B. R., Luk, A. O., Di Ruggiero, E. & Chan, J. C. N. Cardiovascular outcomes trials in type 2 diabetes: time to include young adults. Diabetes Obes. Metab. 22, 3–5 (2020).
Jin, X. et al. Women’s participation in cardiovascular clinical trials from 2010 to 2017. Circulation 141, 540–548 (2020).
Kidney Disease Improving Global Outcomes. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 3, 1–150 (2013).
Levin, A. et al. International consensus definitions of clinical trial outcomes for kidney failure: 2020. Kidney Int. 98, 849–859 (2020).
Siew, E. D. et al. Timing of recovery from moderate to severe AKI and the risk for future loss of kidney function. Am. J. Kidney Dis. 75, 204–213 (2020).
Ke, C., Narayan, K. M. V., Chan, J. C. N., Jha, P. & Shah, B. R. Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations. Nat. Rev. Endocrinol. 18, 413–432 (2022).
Draznin, B. et al. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2022. Diabetes Care 45, S144–S174 (2022).
Davies, M. J. et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 45, 2753–2786 (2022).
Cosentino, F. et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur. Heart J. 41, 255–323 (2020).
Mahaffey, K. W. et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study). Circulation 137, 323–334 (2018).
Codina, P. et al. Head-to-head comparison of contemporary heart failure risk scores. Eur. J. Heart Fail. 23, 2035–2044 (2021).
Shao, H. et al. Addressing regional differences in diabetes progression: global calibration for diabetes simulation model. Value Health 22, 1402–1409 (2019).
Giorgino, F., Caruso, I., Moellmann, J. & Lehrke, M. Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure. Metabolism 104, 154045 (2020).
Dave, C. V. et al. Risk of cardiovascular outcomes in patients with type 2 diabetes after addition of SGLT2 inhibitors versus sulfonylureas to baseline GLP-1RA therapy. Circulation 143, 770–779 (2021).
Mancini, G. B. J. et al. 2022 Canadian Cardiovascular Society Guideline for use of GLP-1 receptor agonists and SGLT2 inhibitors for cardiorenal risk reduction in adults. Can. J. Cardiol. 38, 1153–1167 (2022).
Draznin, B. et al. 11. Chronic kidney disease and risk management: standards of medical care in diabetes-2022. Diabetes Care 45, S175–S184 (2022).
Birkeland, K. I. et al. How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study. Diabetes Obes. Metab. 21, 968–974 (2018).
So, W. Y. et al. Effects of protocol-driven care versus usual outpatient clinic care on survival rates in patients with type 2 diabetes. Am. J. Manag. Care 9, 606–615 (2003).
Pressman, A., Avins, A. L., Neuhaus, J., Ackerson, L. & Rudd, P. Adherence to placebo and mortality in the beta blocker evaluation of survival trial (BEST). Contemp. Clin. Trials 33, 492–498 (2012).
van den Driessen Mareeuw, F., Vaandrager, L., Klerkx, L., Naaldenberg, J. & Koelen, M. Beyond bridging the know-do gap: a qualitative study of systemic interaction to foster knowledge exchange in the public health sector in the Netherlands. BMC Public Health 15, 922 (2015).
Hunter, D. J. Meeting the challenge of the “Know-Do” gap comment on “CIHR Health System Impact Fellows: Reflections on ‘Driving Change’ Within the Health System”. Int. J. Health Policy Manag. 8, 498–500 (2019).
Kazemian, P., Shebl, F. M., McCann, N., Walensky, R. P. & Wexler, D. J. Evaluation of the cascade of diabetes care in the United States, 2005–2016. JAMA Intern. Med. 179, 1376–1385 (2019).
Chan, J. C. N. et al. From Hong Kong diabetes register to JADE program to RAMP-DM for data-driven actions. Diabetes Care 42, 2022–2031 (2019).
Van Spall, H. G. C., Fonarow, G. C. & Mamas, M. A. Underutilization of guideline-directed medical therapy in heart failure: can digital health technologies PROMPT change? J. Am. Coll. Cardiol. 79, 2214–2218 (2022).
Nelson, A. J. et al. Gaps in evidence-based therapy use in insured patients in the United States with type 2 diabetes mellitus and atherosclerotic cardiovascular disease. J. Am. Heart Assoc. 10, e016835 (2021).
Mosenzon, O. et al. CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries. Cardiovasc. Diabetol. 20, 154 (2021).
Chan, J. C. What can we learn from the recent blood glucose lowering megatrials? J. Diabetes Investig. 2, 1–5 (2011).
Eichler, H. G. et al. Bridging the efficacy-effectiveness gap: a regulator’s perspective on addressing variability of drug response. Nat. Rev. Drug Discov. 10, 495–506 (2011).
Manne-Goehler, J. et al. Health system performance for people with diabetes in 28 low- and middle-income countries: a cross-sectional study of nationally representative surveys. PLoS Med. 16, e1002751 (2019).
Lim, L. L. et al. Aspects of multicomponent integrated care promote sustained improvement in surrogate clinical outcomes: a systematic review and meta-analysis. Diabetes Care 41, 1312–1320 (2018).
Hoo, J. X. et al. Impact of multicomponent integrated care on mortality and hospitalization after acute coronary syndrome: a systematic review and meta-analysis. Eur. Heart J. Qual. Care Clin. Outcomes https://doi.org/10.1093/ehjqcco/qcac032 (2022).
Lim, L. L. et al. Association of technologically assisted integrated care with clinical outcomes in type 2 diabetes in Hong Kong using the prospective JADE Program: a retrospective cohort analysis. PLoS Med. 17, e1003367 (2020).
Jiao, F. F. et al. Five-year cost-effectiveness of the multidisciplinary risk assessment and management programme-diabetes mellitus (RAMP-DM). Diabetes Care 41, 250–257 (2018).
Wan, E. Y. F. et al. Five-year effectiveness of the multidisciplinary risk assessment and management programme-diabetes mellitus (RAMP-DM) on diabetes-related complications and health service uses-a population-based and propensity-matched cohort study. Diabetes Care 41, 49–59 (2018).
Yeung, R. O. et al. Metabolic profiles and treatment gaps in young-onset type 2 diabetes in Asia (the JADE programme): a cross-sectional study of a prospective cohort. Lancet Diabetes Endocrinol. 2, 935–943 (2014).
Ke, C. et al. Excess burden of mental illness and hospitalization in young-onset type 2 diabetes: a population-based cohort study. Ann. Intern. Med. 170, 145–154 (2019).
Sattar, N. et al. Age at diagnosis of type 2 diabetes mellitus and associations with cardiovascular and mortality risks. Circulation 139, 2228–2237 (2019).
Magliano, D. J. et al. Young-onset type 2 diabetes mellitus - implications for morbidity and mortality. Nat. Rev. Endocrinol. 16, 321–331 (2020).
Lim, L. L. et al. Effects of a technology-assisted integrated diabetes care program on cardiometabolic risk factors among patients with type 2 diabetes in the Asia-Pacific Region: the JADE program randomized clinical trial. JAMA Netw. Open 4, e217557 (2021).
Chan, J. C. N. et al. Effect of a web-based management guide on risk factors in patients with type 2 diabetes and diabetic kidney disease: a JADE randomized clinical trial. JAMA Netw. Open 5, e223862 (2022).
Nauck, M. A., Wefers, J. & Meier, J. J. Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. Lancet Diabetes Endocrinol. 9, 525–544 (2021).
Shah, N., Abdalla, M. A., Deshmukh, H. & Sathyapalan, T. Therapeutics for type-2 diabetes mellitus: a glance at the recent inclusions and novel agents under development for use in clinical practice. Ther. Adv. Endocrinol. Metab. 12, 20420188211042145 (2021).
Barrera-Chimal, J. & Jaisser, F. Pathophysiologic mechanisms in diabetic kidney disease: a focus on current and future therapeutic targets. Diabetes Obes. Metab. 22 (Suppl. 1), 16–31 (2020).
Zhou, G., Johansson, U., Peng, X. R., Bamberg, K. & Huang, Y. An additive effect of eplerenone to ACE inhibitor on slowing the progression of diabetic nephropathy in the db/db mice. Am. J. Transl. Res. 8, 1339–1354 (2016).
Bakris, G. L. et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N. Engl. J. Med. 383, 2219–2229 (2020).
Pitt, B. et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N. Engl. J. Med. 385, 2252–2263 (2021).
Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989 (2021).
Gerstein, H. C. et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet 394, 131–138 (2019).
Samms, R. J., Coghlan, M. P. & Sloop, K. W. How may GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol. Metab. 31, 410–421 (2020).
Finan, B. et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci. Transl Med. 5, 209ra151 (2013).
Samms, R. J. et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. J. Clin. Invest. 131, e146353 (2021).
Adriaenssens, A. E. et al. Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake. Cell Metab. 30, 987–996.e6 (2019).
Jastreboff, A. M. et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 387, 205–216 (2022).
Frías, J. P. et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N. Engl. J. Med. 385, 503–515 (2021).
Hernandez, A. F. et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392, 1519–1529 (2018).
Gerstein, H. C. et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N. Engl. J. Med. 385, 896–907 (2021).
Bhatt, D. L. et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N. Engl. J. Med. 384, 129–139 (2021).
L.L.L. reported receiving research grants through her affiliated institutions, honoraria for consultancy and speaker fees from Abbott, AstraZeneca, Boehringer Ingelheim, Merck Sharp & Dohme, Novo Nordisk, Roche, Sanofi, Servier and Zuellig Pharma. E.C. has received speaker fees and/or institutional research support from Hua Medicine, Medtronic, Novartis and Sanofi. J.C.N.C. reported receiving research grants through her affiliated institutions, honoraria and speaker fees from Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Celltrion, Hua Medicine, Lee Powder, Lilly, Merck Sharpe Dohme, Merck Serono, Pfizer, Sanofi, Servier and Viatris Pharmaceutical; she holds patents of genetic markers for predicting diabetes and its complications; she is a co-founder of a biotechnology start-up company, GemVCare, with partial support from the Hong Kong Government Innovation and Technology Commission to provide precision diabetes care, and is Chief Executive Officer of Asia Diabetes Foundation on a pro bono basis.
Peer review information
Nature Reviews Endocrinology thanks the anonymous reviewers for their contribution to the peer review of this work.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
European Diabetes Forum: https://www.eudf.org/
About this article
Cite this article
Lim, LL., Chow, E. & Chan, J.C.N. Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice. Nat Rev Endocrinol (2022). https://doi.org/10.1038/s41574-022-00776-2